Second Quarter 2025 Financial Highlights
During the second quarter of 2025, SI-BONE, Inc. showcased impressive financial results, reflecting a solid performance compared to the previous year. The company reported worldwide revenue of $48.6 million, marking a remarkable growth of 21.7%. In the U.S. market alone, the revenue reached $46.4 million, translating to a growth of 22.8%.
Operational Successes
The operational highlights were equally impressive, with 1,440 active U.S. physicians engaged, marking an increase of approximately 25%. The trailing twelve-month average revenue per territory also improved, reaching $2.1 million, an increase of around 23%. This robust performance is further highlighted by the U.S. government's confirmation of necessary funding for their innovative iFuse TORQ technology.
Financial Results Breakdown
SI-BONE's gross margin improved to 79.8%, reflecting a steady rise of 80 basis points. Meanwhile, the company posted a net loss of $6.2 million, which showed an improvement of 31.2% compared to the same period last year. Furthermore, adjusted EBITDA was recorded at a notable $1.0 million for the quarter, indicating a positive trend in financial health.
Leadership Transition
The company plans significant leadership changes, with Tony Recupero announcing his retirement in February 2026 after an illustrious career as President of Commercial Operations. He will step into an advisory role before his exit, allowing for a smooth transition to Nikolas Kerr, who has been appointed as the new Chief Commercial Officer.
Future Guidance for 2025
Looking ahead, SI-BONE forecasts worldwide revenue for 2025 to be in the range of $195 million to $198 million, representing an anticipated year-over-year growth of approximately 17% to 18%. The company estimates its gross margin will remain between 78.5% and 79.0%, with operational expenses expected to rise around 10% in line with revenue growth.
Cash Flow and Liquidity Position
The company ended the quarter with $145.5 million in cash and equivalents, up slightly from $144.4 million at the end of the previous quarter. The generation of $1.1 million in net cash during this period is an encouraging sign for future operational investments.
Market Presence and Product Launch
In July, SI-BONE successfully launched the iFuse TORQ technology across various European countries, further expanding its market presence and offerings. The transition toward international expansion is expected to fuel additional growth while deepening physician engagement.
Conclusion
Overall, SI-BONE, Inc. is positioned for continued success with strong financial results, an expanding physician network, and innovative technologies that address critical healthcare needs. The planned leadership transition aims to sustain and enhance the company's effectiveness in navigating future challenges and opportunities.
Frequently Asked Questions
What were SI-BONE's financial results for the second quarter of 2025?
SI-BONE reported worldwide revenue of $48.6 million, marking a growth of 21.7% compared to the prior year.
Who is the new Chief Commercial Officer of SI-BONE?
Nikolas Kerr has been appointed as the Chief Commercial Officer, succeeding Tony Recupero who is retiring.
What is the projected revenue growth for SI-BONE in 2025?
The company projects its worldwide revenue to be between $195 million and $198 million, indicating a year-over-year growth of approximately 17% to 18%.
How much cash does SI-BONE have on hand as of June 30, 2025?
SI-BONE reported $145.5 million in cash and equivalents by the end of the second quarter of 2025.
What products did SI-BONE recently launch?
SI-BONE recently launched the iFuse TORQ technology across multiple countries in Europe, enhancing their product offerings.
